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From the first reported role of the transcription factor RUNX2 in osteoblast and chondrocyte differentiation and
migration to its involvement in promigratory/proinvasive behavior of breast, prostate, and thyroid cancer cells,
osteosarcoma, or melanoma cells, RUNX2 currently emerges as a key player in metastasis. In this review, we address
the interaction of RUNX2 with the PI3K/AKT signaling pathway, one of the critical axes controlling cancer growth
and metastasis. AKT, either by directly phosphorylating/activating RUNX2 or phosphorylating/inactivating regulators
of RUNX2 stability or activity, contributes to RUNX2 transcriptional activity. Reciprocally, the activation of the
PI3K/AKT pathway by RUNX2 regulation of its different components has been described in non-transformed and
transformed cells. This mutual activation in the context of cancer cells exhibiting constitutive AKT activation and
high levels of RUNX2 might constitute a major driving force in tumor progression and aggressiveness.
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The products of RUNX (Runt-related transcription factor)
genes comprise a family of three closely related transcrip-
tion factors, RUNX1, RUNX2 and RUNX3. These genes
are defined by a highly conserved 128 amino acid DNA
binding/protein-protein interaction domain, called the
Runt-homology domain [1,2]. RUNX2 is a major determin-
ant of osteoblast differentiation and regulates chondrocyte
proliferation, differentiation and hypertrophy during
endochondral bone formation [3–6].
The involvement of RUNX2 in tumor development,
progression and metastasis is largely documented. Some
evidence indicates a role for RUNX2 in T-cell lymph-
oma, acute myeloid leukemia and multiple myeloma
[1,7–9] and bone metastasis in advanced mammary and
prostate cancer [1,10–12]. However, the role of RUNX2
in promoting tumor development in mammary and
prostate cancer extends beyond its pro-bone metastatic* Correspondence: cohenska@cinj.rutgers.edu
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creativecommons.org/publicdomain/zero/1.0/effects [10,11] and the osteolytic disease associated with
these cancers [13,14]. RUNX2 regulates the expression
of genes intimately associated with tumor progression,
invasion and metastasis and its role in migration and in-
vasion has been documented in different tumor cell
types. RUNX2 siRNA treatment of the prostate cancer
cell line PC3 decreases migration and invasion through
Matrigel in vitro [13]. Overexpression of RUNX2 in the
prostate cancer cell line C4-2B enhances its invasiveness
[15]. In addition, RUNX2 overexpression upregulates
transcription factors (SOX9, SNAI2 and SMAD3) impli-
cated in the process of epithelial to mesenchymal transi-
tion (EMT), whose features include increased motility
and invasion potential. Furthermore, RUNX2 overex-
pression upregulates genes involved in cellular move-
ment and cytoskeleton remodeling [15]. High RUNX2
levels in PC3 cells are associated with development of
large tumors, and increased expression of the two metal-
loproteinases MMP9 and MMP13, OPN and VEGF, and
secreted bone-resorbing factors (PTHrP, IL-8) promoting
osteolytic disease [13]. Similarly, in human breast cancer,
RUNX2 directly regulates the expression of MMP9 and
MMP13 [16–18], bone sialoprotein and OPN [16], IL-8ess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ates invasion of the human breast cancer cell lines
MDA-MB-231 and MCF7 [17]. Interestingly, aberrant
RUNX2 expression induces EMT-like changes in normal
mammary epithelial cells [20] and disrupts normal acini
structure in three-dimensional cultures [19], suggesting
a role for RUNX2 in promoting the early events of
breast cancer progression. RUNX2 also plays a central
role in mediating the pro-migratory and pro-invasive
function of thyroid tumor cells, by activating the expression
of MMP2, MMP13, MMP14 and OPN [21]. SiRNA-
mediated knockdown of RUNX2 in human colon carcin-
oma cells leads to decreased migration and invasion
[22]. The U2OS osteosarcoma cells also demonstrate re-
duced motility following siRNA-mediated depletion of
RUNX2. In addition, genomic promoter occupancy of
RUNX2 in osteosarcoma cells identifies genes involved
in motility, such as FAK/PTK2 or talin (TNL1) [23]. We
also demonstrated that RUNX2 knock down in melan-
oma cell lines significantly inhibits their migration and
invasion potential [24].
In addition, the pro-angiogenic effects of RUNX2 are
highly suggestive of RUNX2 as a major player in tumor
promotion. These effects include endothelial cell prolif-
eration, migration and invasion [25,26], induction of
VEGF expression or RUNX2 physical and functional in-
teractions with another major pro-angiogenic factor,
hypoxia-inducible factor 1-a (HIF1-a) [27,28]. These
studies altogether define the transcription factor RUNX2
as pro-migratory, pro-invasive and pro-angiogenic, in
addition to its role in promoting the early steps of
tumorigenesis in breast cancer and driving the meta-
static bone disease in prostate and breast cancer. In this
review, we are focusing on the functional interrelations
between RUNX2 and the PI3K/AKT pathway, which
contribute to cancer progression.
The oncogenic role of the PI3K/AKT axis on tumor
growth extends beyond its pro-proliferative and survival
effects and includes migration and invasion. One im-
portant contribution is the demonstration that PI3K
function is required for TGFβ-mediated epithelial to
mesenchymal transition (EMT) of the NMuMG mam-
mary epithelial cell line. In addition, PI3K inhibition
blocks both basal and TGFβ-induced cell migration of
mouse breast cancer cell lines [29]. The collaboration of
TGFβ autocrine signaling and the activated PI3K/AKT
pathway plays a key role in cancer progression, causing
the shift in TGFβ/SMAD signaling from its tumor sup-
pressive to its tumor promoting mode [30]. As another
illustration of this concept, AKT-mediated phosphoryl-
ation of the EMT transcription factor TWIST1 leads to
transcriptional activation of the TGFβ2 promoter and
activated TGFβ signaling promoting EMT and breast
cancer metastasis [31].Numerous studies describe the requirement of AKT
signaling for the migration and invasion of tumor cells.
Overexpression of AKT or myristylated AKT (MyrAKT),
which is anchored to the plasma membrane and has a
constitutively active kinase activity, increases the migra-
tion and invasion of a human fibrosarcoma cell line.
This study demonstrates that AKT promotes migration
and invasion in a manner depending on both its
membrane-translocating ability and its kinase activity. In
addition, cell migration and invasion require PI3K-
dependent translocation of AKT at the cell membrane,
as evidenced by the inhibition of AKT translocation, cell
migration and invasion by the PI3K inhibitor LY294002
[32]. The expression of subunit p110α (PI3K) siRNA or
AKT1 siRNA in a human ovarian cancer cell line signifi-
cantly decreases its migration and invasion [33].
CXCL12-mediated MMP-9 expression and chemoinva-
sion is sensitive to PI3K inhibitors in various prostate
cancer cell lines [34]. Also in prostate cancer cells, onco-
genic ETS transcription factors require AKT signaling to
activate a cell migration gene expression program
through ETS/AP-1 binding sequences [35]. Adenoviral
transfer of PTEN into melanoma cells leads to inhibition
of AKT phosphorylation and suppression of melanoma
cell invasion [36]. Similarly, PTEN loss increases inva-
sion of human melanoma cells and non-transformed
melanocytes, with a concomitant shift to phosphoryl-
ation of AKT2 [37]. The adaptor GAB2 involved in the
activation of both RAS-ERK and PI3K/AKT signaling
pathways, is overexpressed in metastatic melanoma, pro-
moting migration and invasion of melanoma cells [38].
In addition, AKT is involved in TGFα-mediated migra-
tion of human osteosarcoma cells [39]. Therefore, the
activation of AKT promotes the EMT, migration and in-
vasion programs in a PI3K-dependent manner.
The implication of RUNX2 in signaling pathways in-
volved in tumorigenesis, such as the transforming
growth factor beta (TGFβ) signaling pathway [40,41], the
WNT pathway [40] and the p53 pathway [42] has been
reviewed thoroughly. Mechanistic studies mainly per-
formed in osteoblasts and chondrocytes and in different
cancer cellular systems shed light into a functional inter-
action and cooperation between RUNX2 and the PI3K/
AKT pathway. In the context of cancer cells, this inter-
action might feed a positive feedback loop for the benefit
of tumor progression.
The PI3K/AKT pathway stimulates RUNX2
expression and activity through direct or indirect
mechanisms (Fig. 1a).
Direct regulation of the PI3K/AKT pathway on RUNX2
expression and activity
In prostate cancer cells, stable expression of constitu-
tively activated AKT (myr-AKT) induces the expression
Fig. 1 Model of RUNX2 and PI3K/AKT reciprocal interaction as a driving force for tumor progression. a. AKT activity results in up regulation of
RUNX2 mRNA, stabilization of RUNX2 protein or activation of RUNX2 transcriptional activity. b. RUNX2 transcriptional activity leads to higher
expression of the PI3K subunits p110β and p85, AKT or mTOR and RICTOR, two major components of the mTORC2 complex. c. Mutual activation
of AKT and RUNX2 in the context of cancer cells might favor tumor progression. A pioneering study [47] shows that RUNX2 and the PI3K/AKT
axis are mutually dependent on each other in the regulation of osteoblast and chondrocyte differentiation and their migration. We propose that
a similar feed-forward loop could operate in tumor cells to potentiate RUNX2 and PI3K/AKT activities and generate the pro-migratory and pro-invasive
behavior of tumor cells. Studies described in paragraphs 1 and 2 support this hypothesis
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PGC, MMP9 and MMP13 [43]. In a model of oxidative
stress-induced vascular smooth muscle cell (VSMC)
calcification, H2O2 induces RUNX2 mRNA and protein
expression, resulting in VSMC calcification [44]. H2O2 also
increases phosphorylated AKT levels. The H2O2-mediated
RUNX2 expression is prevented in the presence of an AKT
inhibitor, suggesting that AKT-mediated induction ofRUNX2 plays a critical role in oxidative stress-induced
VSMC calcification [44]. Interestingly, treatment of colorec-
tal cancer cells with H2O2 results in a dramatic increase in
total AKT and phosphorylated AKT (pAKTS473) levels
[45]. Considering that RUNX2 immunoreactivity in colon
carcinoma cells is associated with their aggressive clinical
behavior in colon carcinoma patients [22], we propose that
in a way similar to VSMC calcification, prevalent oxidative
Cohen-Solal et al. Molecular Cancer  (2015) 14:137 Page 4 of 10stress in cancer [46] could participate in maintaining high
levels of RUNX2 through stimulation of the PI3K/AKT
pathway.
In addition to inducing the expression of RUNX2,
earlier experiments show that activation of the PI3K/Akt
signaling pathway enhances DNA binding of Runx2 and
Runx2-dependent transcription in a mouse osteoblastic
cell line [47]. The promoter activity of osteocalcin in
mouse Runx2-overexpressing osteoblastic cells is en-
hanced by a constitutively active form of Akt1 (Akt1CA)
and suppressed by Akt1 siRNA. Chromatin immunopre-
cipitation (ChIP) assay shows that the complex between
Runx2 and the osteocalcin promoter present in wild-type
osteoblasts disappears in Akt1-/- osteoblasts [48]. In
these studies, no mechanism is proposed for the PI3K/
Akt-mediated increase in Runx2 DNA binding and tran-
scriptional activity. More recently, it was shown in cell-
free assays that AKT phosphorylation of RUNX2 Runt
homology domain enhances its DNA binding potential
on a RUNX2 consensus oligonucleotide. In addition,
mutation in AKT phosphorylation sites (generated by sub-
stitution of S203/T205 (double mutant) or S203/T205/S207
(triple mutant) by Alanines) produces RUNX2 forms that
have a reduced ability to bind the RUNX2 consensus oligo-
nucleotide. Expression of the double or triple mutants of
RUNX2 in breast cancer cells reduces the mRNA levels of
two metastasis-related target genes, MMP9 and MMP13,
and reduces the RUNX2-dependent invasive potential of
breast cancer cells. This study establishes RUNX2 as an
AKT substrate and an important mediator of PI3K/AKT
signaling in breast cancer [49].
Indirect regulation of the PI3K/AKT pathway on RUNX2
expression and activity
In addition to transcriptional effects of the PI3K/AKT
pathway on RUNX2 expression, RUNX2 protein levels
are also indirectly regulated by stabilization via AKT. In
osteoblasts, RUNX2 interaction with the E3 ubiquitin
ligase SMURF2 induces degradation of RUNX2 in an
ubiquitin/proteasome-dependent manner [50]. During
osteoblast differentiation, AKT interacts with and phos-
phorylates SMURF2. In addition, AKT enhances ubiquitin/
proteasome-mediated degradation of SMURF2, counteract-
ing the SMURF2-induced degradation of RUNX2. There-
fore, RUNX2 increased stability by AKT is mediated by
SMURF2 in osteoblasts [51]. It will be interesting to inves-
tigate whether some tumor suppressive functions of
SMURF2 [52] could be related to its negative effects on
RUNX2 and whether AKT-mediated degradation of
SMURF2 can occur in tumors, explaining the high levels
of RUNX2 in certain types of cancer [40].
A novel function of FOXO1 and FOXO3 in negatively
regulating RUNX2 stability has been delineated in
vascular smooth muscle cells (VSMC). FOXO1/FOXO3knockdown inhibits RUNX2 ubiquitination, increasing
RUNX2 abundance. Activation of AKT, either by PTEN
deficiency or by overexpression of constitutively acti-
vated AKT, leads to nuclear exclusion of FOXO1 and
FOXO3 in VSMC [53]. In the context of cancer cells,
constitutive AKT activation would favor FOXO1/O3 nu-
clear exclusion, thereby decreasing RUNX2 ubiquitina-
tion and degradation and increasing RUNX2 stability.
These studies altogether show that AKT activity posi-
tively regulates RUNX2 stability through ubiquitin/
proteasome-mediated degradation of SMURF2 or nu-
clear exclusion of FOXO1 and FOXO3, depending on
the cellular system.
Additional studies demonstrate that AKT also positively
regulates RUNX2 activity through indirect mechanisms, in-
volving FOXO1, FOXO4 and Glycogen Synthase Kinase 3β
(GSK3β). The transcription factor FOXO1 physically inter-
acts with RUNX2 in osteoblastic cells and in COS-7 cells
and inhibits RUNX2 binding to its cognate site within the
osteocalcin promoter. Upon IGF1/insulin binding to their
receptors, activation of the PI3K/AKT pathway leads to
phosphorylation and nuclear exclusion of FOXO1 and re-
activation of RUNX2 [54]. This indirect mechanism of
RUNX2 activation by the PI3K/AKT pathway is also
described in human tumor cells. FOXO1 interacts with
RUNX2 in vitro and in prostate cancer cells, and inhibits
RUNX2 transcriptional activity on the OP, IL8, VEGF and
MMP13 genes. FOXO1 also inhibits RUNX2-mediated mi-
gration and invasion of prostate cancer cells [55]. The loss
of PTEN in prostate cancer cells leads to activation of AKT
and phosphorylation and retention of FOXO1 in the cyto-
plasm. The FOXO1 phosphorylation by AKT therefore
abolishes FOXO1-mediated inhibition of RUNX2 and fa-
vors RUNX2-mediated gene expression, migration and in-
vasion [55]. Interestingly, expression of PTEN and the level
of FOXO1 in the nucleus inversely correlate with RUNX2
expression in prostate cancer specimens from patients with
lymph nodes or bone metastasis [55]. As demonstrated in
prostate cancer, FOXO4 antagonizes RUNX2 activity by
physically interacting with and preventing RUNX2 to in-
duce the expression of pro-metastatic genes, such as PIP
and PGC [43]. As for FOXO1, AKT phosphorylation of
FOXO4 results in its retention in the cytosol [56]. There-
fore, in the case of hyperactive AKT signaling, the retention
of FOXO4 in the cytoplasm prevents this antagonism,
thereby reactivating RUNX2 and favoring expression of
RUNX2-dependent metastasis genes [43]. Phosphorylation
of RUNX2 at S369-S373-S377 by Glycogen Synthase Kinase
3β (GSK3β) attenuates the transcriptional activity of
RUNX2, explaining the suppression of bone formation
by overexpression of wild-type GSK3β or constitu-
tively active form of GSK3β (CA-GSK3β) [57]. Since
AKT phosphorylates GSK3β at S9 causing its inactiva-
tion [58], we postulate that AKT activation will result
Cohen-Solal et al. Molecular Cancer  (2015) 14:137 Page 5 of 10in GSK3β inactivation and restoration of RUNX2
transcriptional activity. Therefore, in tumor cells exhi-
biting constitutive activation of the PI3K/AKT path-
way, by various mechanisms such as RAS mutation,
PTEN deletion, PI3K mutation, or receptor tyrosine
kinase overexpression, it is conceivable that GSK3β in-
activation will prevent the repression of RUNX2 tran-
scriptional activity.
RUNX2 activates the PI3K/AKT pathway by
regulating its components (Fig. 1b).
Direct control of RUNX2 on the expression of the PI3K/
AKT pathway components
The regulation of PI3K and Akt protein levels by
RUNX2 was initially demonstrated in the context of
mouse osteoblast and chondrocyte differentiation. This
work shows that Runx2 upregulates PI3K subunits p85
and PIK3CB (p110β) and the kinase Akt. p110β is
mainly regulated at the transcriptional level, while p85
and Akt are regulated at both transcriptional and pro-
tein levels [47]. A similar mechanism is described in
the megakaryocytic leukemia (AMkL) cell line Meg-01.
RUNX1 directly binds to the RUNX1 binding sites of the
PI3KCD (P110DELTA) promoter and the PI3KCD gene is
a direct transcriptional target of RUNX1 in the Meg-01
cells [59].
Indirect regulation of RUNX2 on the PI3K/AKT signaling
pathway
The indirect regulation of RUNX2 on the PI3K/AKT sig-
naling pathway has been documented in prostate and
breast cancer cells. In androgen-independent prostate
cancer cell lines, knocking down or overexpressing
RUNX2 leads to a decreased or increased level of phos-
phorylated AKT at serine 473 (pAKTS473) respectively
by mechanisms yet to be defined [60]. A novel mechan-
ism to activate AKT activity is demonstrated in invasive
breast cancer cells. Endogenous RUNX2 is required to
maintain high levels of pAKTS473 in invasive cancer
cells, but not in non-invasive breast cancer cells or nor-
mal cells. RUNX2 knockdown in the invasive cancer
cells results in the decrease of mRNA and proteins levels
of both mTOR and RICTOR, two major components of
the mTORC2 complex involved in phosphorylating AKT
on serine 473. The effect on mTOR expression is medi-
ated through direct binding of RUNX2 to the mTOR
promoter region (-2420 to -2441) containing two
highly conserved RUNX binding elements at -2420
and -2430 bp. Therefore, RUNX2 up regulates compo-
nents of the mTORC2 complex, which directly phos-
phorylates AKT [61].
An additional illustration of an indirect regulation of
RUNX2 on the PI3K/AKT pathway comes from genomic
promoter occupancy of RUNX2 in osteosarcoma cells.This analysis identifies genes involved in cell adhesion and
motility, such as FAK [23], which also signals through the
PI3K/AKT pathway [62]. Therefore, in osteosarcoma cells,
RUNX2 could stimulate the PI3K/AKT pathway through
the positive regulation of FAK. We also demonstrated that
knocking down RUNX2 in human melanoma cells results
in decreased levels of the FAK protein [24] and our recent
experiments show that RUNX2 regulates FAK mRNA (un-
published results). Therefore, also in melanoma, RUNX2
could regulate the PI3K/AKT pathway through FAK up-
regulation.
Integration of the TGFβ signaling pathway in the
RUNX2/AKT feedback loop
In the context of cancer cells, the positive feedback loop
illustrated in Figs. 1 and 2 integrates another important
player in tumor progression, the TGFβ signaling path-
way, in the establishment of a major process involved in
migration, invasion and metastasis, the epithelial to
mesenchymal transition (EMT). The role of TGFβ in
cancer-associated EMT is largely documented [63]. In
TGFβ-induced EMT, the downstream effectors SMADs
(SMAD2 and SMAD3) stimulate gene reprogramming,
by activating directly or indirectly the expression of the
master EMT transcription factors SNAI1, SNAI2/SLUG,
ZEB1, ZEB2 and TWIST1 [64,65]. RUNX2 is also a
TGFβ target gene [18,66–68], and RUNX2 is a transcrip-
tional partner for SMADs [41]. An early study shows
that activated SMADs are directed to subnuclear foci
only in the presence of RUNX proteins, and the SMAD-
RUNX complexes are associated in situ with the nuclear
matrix. In addition, RUNX2 recruits SMADs to sub-
nuclear sites of active transcription [69]. The 391–432
domain of RUNX2 is required for the interaction of
RUNX2 with SMAD3. Thus, the Smad-interacting do-
main (SMID) in RUNX2 overlaps the nuclear matrix tar-
geting signal [70]. The partnership between RUNX2 and
SMADs in promoting EMT and tumor progression is il-
lustrated in human breast and prostate cancer. In re-
sponse to TGFβ, RUNX2 interacts with SMAD3 and
JUNB at the distal runt domain (RD) site of the MMP13
(collagenase-3) promoter in MDA-MB-231 breast cancer
cells [18]. RUNX2 induces EMT, with increased expres-
sion of the EMT-related transcription factor SNAI2 and
decreased expression of E-cadherin in breast cancer
cells. Inhibition of TGFβ signaling suppresses RUNX2-
stimulated SNAI2 expression [71]. Using a reporter
carrying TGFβ responsive motifs flanked by RUNX2
motifs (3x-multimerized TGFβRE-luciferase reporter),
luciferase assays show that RUNX2 synergizes with
TGFβ/SMADs to increase the promoter activity of the
reporter in PC3-a prostate cancer cells [72]. siRNA-
mediated RUNX2 depletion impaired the positive
































Fig. 2 Summary of the interactions between the PI3K/AKT pathway and RUNX2 with integration of the TGFβ pathway. Some genes regulated
by RUNX2 and supporting different aspects of tumor progression are represented. The activation of growth factor receptors, such as G-protein
coupled receptors (GPCR), receptor tyrosine kinases (RTKs), TGFβ receptor, results in successive activation of PI3K and AKT. PTEN inactivation also
results in activation of PI3K and AKT. AKT activation positively regulates RUNX2 expression and activity by direct and indirect mechanisms as
shown in Fig. 1A. Reciprocally, RUNX2 activates the PI3K/AKT pathway by regulation if its components, PI3K and AKT, or regulation of mTOR and
RICTOR, two majors components of mTORC2, which phosphorylates AKT on serine 473. Upon receptor activation, the kinases ERK and p38 also
phosphorylate and activate RUNX2. Through partnering with SMADs transcription factors, RUNX2, (TGFβ target gene itself) activates the expression
of genes involved in EMT, invasion and the metastatic cascade, angiogenesis and bone disease. OPN: osteopontin; BSP: Bone sialoprotein; MMP:
Matrix metalloproteinase; FAK: Focal adhesion kinase; IHH: Indian hedgehog; PTHrP: Parathyroid hormone-related protein; VEGF: Vascular endothelial growth
factor; IL8: Interleukin-8. IL11: Interleukin-11; PAI-1: Plasminogen activator inhibitor-1
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enchymal marker of the EMT program in thyroid can-
cer, controlling invasiveness of thyroid tumors [73].
Similarly, RUNX2 silencing in human thyroid cancer
cell lines results in decreased mRNA expression of
SNAI2 and invasion [74].
In addition to the interdependence of RUNX2 and
the TGFβ signaling pathway during the EMT process,
the RUNX2-SMADs partnership is central for tumor
growth, metastasis and bone disease. RUNX2 is an inte-
gral part of TGFβ-mediated PTHrP and cyclin D1 gene
regulation in breast cancer cells, facilitating the vicious
cycle of cancer cell survival and osteolytic disease [14].
Mutation of three residues in RUNX2 leading to im-
paired recruitment of SMADs to RUNX2 subnuclear foci
reduces prostate tumor size and osteolytic disease in theintratibial model. This study also identifies that VEGF
and osteolytic related genes such as osteoprotegerin, PAI-
1, PTHrP and IL-11 are under the control of the
RUNX2-SMAD interaction [75]. Furthermore, RUNX2-
SMAD interaction is crucial for distal metastasis of pros-
tate cancer cells from bone to lung [75].
The mechanisms involved in the cooperation between
TGFβ and PI3K/AKT in cancer progression have been
reviewed extensively [30,76]. This cooperation takes
place in advanced cancer stages to promote EMT, and
subsequent migration, invasion and metastasis. This
signaling interplay includes a SMAD-independent, rapid
induction of AKT phosphorylation by TGFβ and an in-
direct activation of PI3K/AKT by TGFβ-induced miRNA
expression [30]. Reciprocally, PI3K/AKT activation pro-
motes TβRI stability for sustained TGFβ signaling. The
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potent enhancer of TGF-β signaling by directly deubi-
quitylating the receptor TβRI, thereby maintaining
sustained TβRI levels at the plasma membrane. AKT
phosphorylates USP4, leading to USP4 relocalization to the
membrane, reinforcing the pro-tumorigenic functions of
TGFβ [77]. In addition, AKT directly phosphorylates
TWIST1 at Ser42 to promote TWIST1-mediated expres-
sion of TGFβ2, leading to enhanced TGFβ signaling in
breast cancer cells [31]. Furthermore, activation of the
PI3K/AKT pathway phosphorylates and inactivates GSK3β,
suppressing GSK3β-mediated negative regulation of an-
other EMT factor, SNAIL in breast cancer cells [78].
Therefore, the positive feedback loop between PI3K/
AKT and RUNX2 strengthens the collaboration between
SMADs and RUNX2 and between PI3K/AKT and TGFβ
and participates in the reprogramming of cancer cells to
express EMT transcription factors, MMPs, VEGF, bone
matrix proteins, bone-resorbing factors, and other prod-
ucts of genes associated with invasion and metastasis.
Interestingly, growing evidence shows that the EMT
transcription factors regulate not only EMT and tumor
invasiveness but also multiple hallmarks of cancer, in-
cluding angiogenesis, sustained proliferative signaling,
evasion from growth inhibitory signals, or resisting cell
death by conferring resistance to chemotherapy and
radiotherapy [79].
Contribution of the RAS/MAPK pathway and PI3K/
AKT-RAS/MAPK cross-talk to RUNX2 activity
In response to growth factors stimulation, receptor tyro-
sine kinases (RTKs) and other membrane receptors
activate the RAS/MAPK/ERK and PI3K/AKT signaling
pathways [80,81]. In the context of cancer cells where
autocrine and paracrine activation of growth factor re-
ceptors contribute to tumor progression, RUNX2 under-
goes phosphorylation by both ERK and AKT kinases.
ERK phosphorylation sites in RUNX2 (S43, S301, S309
and S510) have been identified and functionally charac-
terized [82]. The double S301A/S319A phosphorylation
site mutation significantly reduces expression of VEGF,
MMP9 and SPP1, migration and invasion of human
prostate cancer cell lines and in vivo growth of tumor
cell xenografts [83]. Another study demonstrates that ac-
tivation of the TAK1-MKK3/6-p38 MAPK axis leads to
phosphorylation of RUNX2 by p38, promoting RUNX2
association with the co-activator CREB-binding protein,
CBP, which is required to regulate osteoblast genetic
programs [84]. Signaling crosstalk represents an import-
ant component regulating RUNX2 as a driver of tumor
progression via phosphorylation. The phosphorylation of
RUNX2 by AKT, ERK and p38 and the effect of these
phosphorylation events on RUNX2 activity have to be
contextualized in tumor cells exhibiting continuouscross-talk between the RAS/MAPK and PI3K/AKT
pathways [80]. In addition to being a downstream target
of this crosstalk, RUNX2 also acts on this crosstalk.
RUNX2 promotes the crosstalk between MEK/ERK and
PI3K/AKT via EGFR in human MCF-10A mammary epi-
thelial cells [85].
Conclusion
The transcription factor RUNX2 and the PI3K/AKT axis
are key players of EMT, migration and invasion. Overex-
pression of activated RUNX2 and hyperactivation of
AKT represent two characteristics of pro-migratory and
pro-invasive tumor cells. As shown in non-transformed
and transformed cells, the PI3K/AKT pathway directly
or indirectly stimulates RUNX2 expression and activity,
while RUNX2 activates the PI3K/AKT pathway by the
regulation of its components or mTORC2. In the con-
text of cancer cells, this reciprocal activation may set the
stage for uncontrolled expression of genes involved in
promoting tumor progression (Figs. 1c and 2). However,
some important questions remain unanswered: How
does AKT participate in the switch of RUNX2 from a
tumor suppressor [86] to a pro-oncogenic factor at ad-
vanced stages of cancer? What is the role of the RAS/
MAPK-PI3K/AKT crosstalk in this switch? In addition
to phosphorylating and inhibiting negative regulators of
RUNX2, such as FOXO factors, SMURF2 or GSK3β, what
interactions between RUNX2 and other transcription fac-
tors/co-activators are promoted by direct phosphorylation
of RUNX2 by AKT? What metastasis-related genes are
induced by these AKT-mediated interactions? Can these
AKT-mediated interactions between RUNX2 and other
transcription factors/co-activators be targeted as opposed
to targeting RUNX2 alone, which remains a challenge? As
it appears that two or even the three RUNX proteins are
often co-expressed in tumor cells, how does the phosphor-
ylation of RUNX1 and RUNX3 by AKT modulate the ef-
fects of AKT-mediated RUNX2 phosphorylation on tumor
progression? Are these modulations mediated through dir-
ect or indirect interactions between RUNX2 and RUNX1
or RUNX3? Understanding how partnership between
transcription factors/co-activators can promote the ex-
pression of genes involved in tumor progression might be
an indispensable step to overcome the present challenge
of targeting pro-oncogenic transcription factors, tradition-
ally considered undruggable.
Although the focus of this review is the PI3K/AKT and
RUNX2 mutual activation, the integration of the TGFβ
signaling pathway in this positive feedback loop further
illustrates the complexity of the interactions governing
tumor progression, which warrants a comparable level
of complexity for the design of new treatments for can-
cer patients. Therefore, the identification of such posi-
tive feedbacks loops in tumor cells may provide insight
Cohen-Solal et al. Molecular Cancer  (2015) 14:137 Page 8 of 10into potential new combination treatments. Instead of
targeting one player of the metastatic process, inevitably
resulting in resistance mechanisms, simultaneous target-
ing of partners of positive feedbacks loops, such as
PI3K/AKT, RUNX2 and TGFβ, may substantially com-
promise the strategies developed by tumor cells to gen-
erate resistance mechanisms.
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